Vimab Holding Ab entered into a conditional share transfer agreement to acquire Headsent AB (publ) (OM:VIMAB) in a reverse merger for approximately SEK 150 million on May 31, 2022. The purchase price amounts to SEK 150 million and will be paid through reverses which must be set off against 16,681,543 shares in Headsent. In connection with the acquisition, Headsent intends to change its company name to VIMAB Group AB (publ). The acquisition of Vimab is mainly conditional on, the extraordinary general meeting of Headsent approves the acquisition, the general meeting decides on the receipt issue and other necessary decisions to be able to carry out the transaction, Nasdaq Stockholm AB, after a relisting process, approves for continued listing on Nasdaq First North and other customary admission conditions. The board of directors of Headsent proposes that the shareholders vote in favor of the transaction at the general meeting. As of July 27, 2022, the transaction has been approved at the general meeting of shareholders. The transaction and the review process are expected to be completed in the third quarter of 2022.
Vimab Holding Ab completed the acquisition of Headsent AB (publ) (OM:VIMAB) in a reverse merger on July 27, 2022